Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

619
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
619
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathomorphological Features of Lung Damage Caused by Infection with Various Variants of SARS-CoV-2 in Humanized Model Animals.

Doklady. Biochemistry and biophysics·2026
Same author

Isolation, Purification, and Structural-Functional Analysis of Recombinant Human Transferrin Produced by the Methylotrophic Yeast Strain Pichia pastoris.

Bulletin of experimental biology and medicine·2026
Same author

Exploring coding and signal joints of novel TCR beta D-D rearrangements for tracking T-cell leukemia clonality.

Experimental hematology & oncology·2025
Same author

The Impact of the Intracellular Domains of Chimeric Antigenic Receptors on the Properties of CAR T-cells.

Acta naturae·2025
Same author

Specific Matrix on the Basis of Angiotensin-Converting Enzyme 2: Development and Functional Analysis.

Bulletin of experimental biology and medicine·2025
Same author

Heterologous Production of Antimicrobial Peptides in Yeast Allows for Massive Assessment of the Activity of DNA-Encoded Antimicrobials In Situ.

Acta naturae·2025

Related Experiment Video

Updated: Aug 14, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

992

Barnase-barstar Specific Interaction Regulates Car-T Cells Cytotoxic Activity toward Malignancy.

R S Kalinin1, V O Shipunova2, Y P Rubtsov2

  • 1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. Roman.Kalinin.93@yandex.ru.

Doklady. Biochemistry and Biophysics
|January 18, 2023
PubMed
Summary

Researchers developed a novel barnase-barstar system to control Chimeric Antigen Receptor T-cell (CAR-T) therapy. This system enhances safety by regulating CAR-T cell activity, addressing limitations in current cancer treatments.

Keywords:
Barnase-barstar interactionCAR-T cellsDARPinssolid tumors

More Related Videos

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:16

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

170
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

Related Experiment Videos

Last Updated: Aug 14, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

992
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:16

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

170
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized cancer treatment.
  • Current CAR-T therapies face limitations due to challenges in controlling pharmacokinetics and pharmacodynamics.
  • Severe medical complications necessitate methods to regulate CAR-T cell activity in vivo.

Purpose of the Study:

  • To propose and evaluate the barnase-barstar system for controlling the cytotoxic antitumor activity of CAR-T cells.
  • To develop a controllable CAR-T therapy by managing its in vivo activity.

Main Methods:

  • Utilized the barnase-barstar system for inducible regulation of CAR-T cell activity.
  • Developed barstar-modified CAR-T cells for controlled interaction with barnase-based molecules.
  • Fused barnase with designed ankyrin repeat proteins (DARPins) targeting HER2 (human epidermal growth factor receptor 2).

Main Results:

  • Demonstrated pronounced regulatory effects on CAR-T cell targeting activity.
  • Successfully managed the activity of CAR-T cells using the barnase-barstar system.
  • Showcased the potential for enhanced safety and efficacy in CAR-T therapy.

Conclusions:

  • The barnase-barstar system offers a viable strategy for controlling CAR-T cell activity.
  • This approach addresses critical limitations in current CAR-T therapies, improving safety profiles.
  • Further development of this system could lead to more effective and safer cancer immunotherapies.